Clinical Trials Logo

Lymphoma, T-Cell, Peripheral clinical trials

View clinical trials related to Lymphoma, T-Cell, Peripheral.

Filter by:

NCT ID: NCT01839097 Completed - Clinical trials for Peripheral T-cell Lymphoma

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Start date: May 2013
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.

NCT ID: NCT01822886 Completed - Clinical trials for Peripheral T-cell Lymphoma

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

FIL_GEMRO
Start date: January 2013
Phase: Phase 2
Study type: Interventional

Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin (GEMRO) regimen as salvage treatment in relapsed/refractory PTCL (peripheral T-cell lymphoma) in a selected population of patients.

NCT ID: NCT01806337 Completed - Clinical trials for Peripheral T-Cell Lymphoma

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

Start date: July 2003
Phase: Phase 2
Study type: Interventional

Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation

NCT ID: NCT01796002 Completed - Clinical trials for Peripheral T-cell Lymphoma

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Start date: January 2013
Phase: Phase 3
Study type: Interventional

Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC).

NCT ID: NCT01777152 Completed - Clinical trials for Non-Hodgkin Lymphoma

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

ECHELON-2
Start date: January 31, 2013
Phase: Phase 3
Study type: Interventional

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

NCT ID: NCT01776411 Completed - Clinical trials for Recurrent or Refractory PTCL

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Start date: January 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I portion: To confirm safety and tolerability in recurrent/refractory peripheral T-cell lymphoma patients during repeated oral administration of forodesine 300 mg twice daily (600 mg/day) for 28 days, and determine the recommended dose. Also, to evaluate pharmacokinetics. Phase II portion: To evaluate the efficacy, safety, and pharmacokinetics of the recommended dosage regimen determined in the phase I portion. The primary efficacy endpoint shall be objective response rate (ORR).

NCT ID: NCT01767766 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Start date: January 7, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in patients with advanced hematologic malignancies.

NCT ID: NCT01748721 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Start date: November 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them

NCT ID: NCT01728805 Completed - Clinical trials for Cutaneous T-Cell Lymphoma

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Start date: November 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.

NCT ID: NCT01716806 Completed - Hodgkin Disease Clinical Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Start date: October 31, 2012
Phase: Phase 2
Study type: Interventional

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.